Qitao Yu

发表

Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).

Chengping Hu, Gang Wu, Yong Fang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy

Shaozhang Zhou, Qitao Yu, Shubin Chen, 2021, Frontiers in Oncology.

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

Jianji Pan, W. Feng, Xiaozhong Chen, 2021, Journal for ImmunoTherapy of Cancer.

Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

Ying Cheng, Dong Wang, Yuankai Shi, 2020 .

Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.

Gong-yan Chen, Yun-peng Yang, Zhehai Wang, 2022, Lung cancer.

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

Qinghua Zhou, Yiping Zhang, Z. Guan, 2005, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis

Jianbo He, Xiaoning Zhong, Ruiling Ning, 2022, Computational and mathematical methods in medicine.

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review

Wei Jiang, Y. Shao, Ruiling Ning, 2020, OncoTargets and therapy.

Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse

R. Deberardinis, Zeping Hu, Wei Jiang, 2022, The Journal of clinical investigation.

Ef ﬁ cacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Ying Cheng, R. Guo, Yiping Zhang, 2022 .

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study

Wei Jiang, Jianbo He, Wenhua Zhao, 2022, Frontiers in Immunology.

Practices and Hindrances in Cancer Pain Management: Results of a National Multi-Cancer Center Survey Among Healthcare Professionals in China

Yuanyuan Zhao, Ning Li, Qitao Yu, 2021, Cancer management and research.

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer

Wei Jiang, Shaozhang Zhou, Qitao Yu, 2020, Cancer medicine.

Prognostic Value of Pretreatment Albumin-to-Alkaline Phosphatase Ratio in Extensive-Disease Small-Cell Lung Cancer: A Retrospective Cohort Study

Wei Jiang, Aiping Zeng, Shaozhang Zhou, 2020, Cancer management and research.

CMAR_A_247967 2015..2024

Wei Jiang, Aiping Zeng, Shaozhang Zhou, 2020 .

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study.

Baolan Li, Wei-min Li, B. Peng, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation

Wei Jiang, Shaozhang Zhou, Qitao Yu, 2019, OncoTargets and therapy.

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First‐Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open‐label, Randomized, Phase III Trial

Chengping Hu, Gang Wu, Shun Lu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Wei Jiang, Jianbo He, Qitao Yu, 2021, Frontiers in Oncology.

Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis

Wei Jiang, Changyuan Wei, Ruiling Ning, 2018, OncoTargets and therapy.

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).

Ying Cheng, B. Han, Baolan Li, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer.

Yu Zhang, Tao Li, Tao Li, 2015, International journal of clinical and experimental pathology.

Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer

Jianbo He, Yun Zhao, Shaozhang Zhou, 2021, Journal of Cancer.

Case Report of Thymoma Tumor Reduction Following Plasmapheresis

Qitao Yu, Wei-zhe Jiang, 2015, Medicine.

The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching

Huiqin Jiang, Shaozhang Zhou, Qitao Yu, 2022, Journal of Cancer.

Ying Cheng, Baolan Li, Yunpeng Liu, 2019, Translational lung cancer research.

RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.

Ji-Rong Wen, Xiaozhong Chen, Guihua Wang, 2022, Journal of Clinical Oncology.

The predictive value of pretreatment haemoglobin-to-red cell distribution width ratio for overall survival of patients with advanced non-small cell lung cancer: a propensity score matching analysis

Wei Jiang, Jianbo He, Huiqin Jiang, 2021, The Journal of international medical research.

Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial

Z. Sha, Zibin Liang, Xiaofeng Pei, 2020, Annals of translational medicine.

Wogonoside induces apoptosis in human non-small cell lung cancer A549 cells by promoting mitochondria dysfunction.

Ruiling Ning, Shaozhang Zhou, M. Luo, 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

Fei Liu, Jian Feng, N. Yang, 2023, BMC Medicine.

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.

Ying Cheng, Dong Wang, Yuankai Shi, 2021, The Lancet. Respiratory medicine.

Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)

K. Goto, Jialei Wang, D. Zhong, 2022, Cancer Research.

Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines

Aiping Zeng, Shaozhang Zhou, Qitao Yu, 2018, Anti-cancer drugs.

SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

X. Yi, Y. Guan, W. Cao, 2023, BMC Cancer.

The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials

Shaozhang Zhou, Wei Jiang, Qitao Yu, 2023, Frontiers in immunology.

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

W. Liang, Chuanhao Tang, Jin-liang Wang, 2023, Journal of the National Cancer Center.

The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).

Yunpeng Liu, N. Yang, M. Tao, 2022, Journal of Clinical Oncology.

AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial

M. Zhou, W. Zhang, Yanqiu Zhao, 2023, EClinicalMedicine.

A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.

Yanqiu Zhao, Li Zhang, Lin Wang, 2022, Journal of Clinical Oncology.

NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report

Qinhan Hou, Ruiling Ning, Qitao Yu, 2022, Frontiers in Oncology.

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

Ying Cheng, Yanqiu Zhao, N. Yang, 2023, Signal transduction and targeted therapy.

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

Wei Jiang, Qitao Yu, Shubin Chen, 2023, Frontiers in Medicine.

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review

Wei Jiang, Ruiling Ning, Wenqi Luo, 2023, Frontiers in Oncology.

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).

Hong Wang, Jianji Pan, Xiaozhong Chen, 2023, Cancer cell.

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

N. Yang, M. Tao, Caicun Zhou, 2021 .

A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).

N. Yang, Yu-xiang Ma, Yun Fan, 2023, Lung cancer.

Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.

Qingshan Li, Ying Cheng, R. Guo, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

Jianya Zhou, W. Dong, Qitao Yu, 2024, Therapeutic advances in medical oncology.